AI-driven molecular glue innovation: Insilico nominates ISM9546, an oral, peripheral-restricted VAV1 degrader as PCC for autoimmune diseases
Insilico Medicine nominates ISM0900, a potent, AI-driven, oral Lp(a) inhibitor, as PCC for management of cardiovascular risks - EurekAlert!
AI-empowered pipeline-in-a-drug option: Insilico Medicine nominates ISM9077, potential first-in-class target Y inhibitor, as preclinical candidate (PCC) for ocular diseases, inflammatory disorders and aging - EurekAlert!
Insilico delivers second preclinical candidate compound (PCC) to Fosun Pharma - EurekAlert
